Option Care Health Inc’s filing revealed that its Director Wright Norman L. acquired Company’s shares for reported $99976.0 on Sep 09 ’25. In the deal valued at $29.31 per share,3,411 shares were bought. As a result of this transaction, Wright Norman L. now holds 15,501 shares worth roughly $0.41 million.
Then, Pate R Carter bought 750 shares, generating $20,391 in total proceeds. Upon buying the shares at $27.19, the Director now owns 41,910 shares.
Before that, KRAEMER HARRY M JANSEN JR bought 36,000 shares. Option Care Health Inc shares valued at $977,278 were divested by the Director at a price of $27.15 per share. As a result of the transaction, KRAEMER HARRY M JANSEN JR now holds 375,390 shares, worth roughly $10.03 million.
TD Cowen initiated its Option Care Health Inc [OPCH] rating to a Hold in a research note published on October 02, 2025; the price target was $30. A number of analysts have revised their coverage, including UBS’s analysts, who increased its forecast for the stock in late April from “a Neutral” to “a Buy”. Jefferies also remained covering OPCH and has increased its forecast on January 23, 2025 with a “Buy” recommendation from previously “Hold” rating. BofA Securities revised its rating on January 13, 2025. It rated OPCH as “a Buy” which previously was an “a Neutral”.
Price Performance Review of OPCH
On Friday, Option Care Health Inc [NASDAQ:OPCH] saw its stock fall -0.34% to $26.71. Over the last five days, the stock has lost -2.87%. Option Care Health Inc shares have fallen nearly -5.32% since the year began. Nevertheless, the stocks have risen 15.13% over the past one year.
How much short interest is there in Option Care Health Inc?
A steep rise in short interest was recorded in Option Care Health Inc stocks on 2025-09-30, growing by 2.33 million shares to a total of 6.98 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 4.65 million shares. There was a rise of 33.37%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 05, 2024 when UBS began covering the stock and recommended ‘”a Neutral”‘ rating along with a $26 price target.
